|  | Percentage change in BMD at 2 yearsb | |||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Lumbar spine | Hip | ||||||
Study (accrual) | Osteoclast inhibitora | Low risk | Intermediate risk on no bisphosphonate | Intermediate risk on bisphosphonate ( P value) | High risk | Low risk | Intermediate risk on no bisphosphonate | Intermediate risk on bisphosphonate ( P value) | High risk |
ARBI [1] (n = 213) | Risedronate 35 mg weekly | (-) 2.5 | (-) 1.5 | (+) 5.7 (0.006) | (+) 6.6 | (-) 5.7 | (-) 3.9 | (+) 1.6 (0.037) | (-) 1.9 |
ARIBON [2] (n = 131) | Ibandronate 150 mg monthly | (-) 4.79 | (-) 3.22 | (+) 2.98 (<0.01) | (+) 3.52 | (-) 3.72 | (-) 3.90 | (+) 0.60 (<0.01) | (+) 2.49 |
SABRE [3] (n = 234) | Risedronate 35 mg weekly | (-) 2.1 | (-) 1.8 | (+) 2.2 (<0.0001) | (+) 3.0 | (-) 0.4 | (-) 1.1 | (+) 1.8 (<0.0001) | (+) 2.0 |